BIO101

Phase 2Small molecule

BBiophytis

BIO101 is one of 59 small molecule programs targeting Weight loss. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossActive, not recruiting

COVID-19Active, not recruiting

Weight LossPhase 2

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1932 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Calciferol

Alnylam Pharmaceuticals

BIO101

1 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Tricor

JJagotec

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Statin

Bristol-Myers Squibb

Preclinical

1 8

Selenium

SSWOG Cancer Research Network

Preclinical

1 9

Tpa

UUniversity of Florida

Preclinical

1 10

Other Tkis

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Weight Loss

NCT07411378

Clinical

Trials by Indication[1]

Clinical Trial1 trial

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Completed·BBiophytis·Phase 2·NCT03452488·233 enrolled

Weight loss1 trial

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Not yet recruiting·BBiophytis·Phase 2·NCT07411378·164 enrolled

COVID-191 trial

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

Terminated·BBiophytis·Phase 2/3·NCT04472728·238 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BIO101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIO101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIO101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biophytis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBiophytis

BIO101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Clinical Trial1 trial

Weight loss1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News